University Of California San Francisco
Nab-paclitaxel plus gemcitabine may benefit some patients with surgically resected pancreatic cancer
Atrial fibrillation more likely with low-carb diet
Smartphone heart rate tech, deep learning may aid in diabetes detection
Background parenchymal enhancement on MRI predicts risk for invasive breast cancer
Background parenchymal enhancement observed on breast MRI appeared to be strongly predictive of risk for breast cancer, regardless of breast density, according to a study published in Journal of Clinical Oncology.“The incorporation of breast density in breast cancer risk models, as well as state-mandated reporting of mammographic breast density to women, underscores the central role of imaging biomarkers in risk assessment,” Vignesh Arasu, MD, a radiologist affiliated with Kaiser Permanente Medical Center and University of California, San Francisco, and colleagues wrote. “Recent studies have explored the predictive value of other breast imaging biomarkers, and accumulating evidence suggests elevated background parenchymal enhancement (BPE) assessed on breast MRI may predict primary breast cancer risk.”
Researchers identify genomic drivers of poor survival, enzalutamide resistance in advanced prostate cancer
Margetuximab extends PFS in HER2-positive metastatic breast cancer
Researchers tap genomic technology to develop personalized treatments for pediatric glioma
Extra caregiving duties heighten risk for burnout among physician mothers
Hooked on ID with Paul A. Volberding, MD

I followed a somewhat circuitous route to a career in ID. In medical school and residency, I was strongly drawn to oncology but got a bit distracted by also falling in love with viruses, especially retroviruses. I worked in research virology labs all through college and medical school, and as retroviruses were considered as potentially causing common cancers in humans, that research was typically found not in ID but rather in oncology divisions. I came to UCSF in 1978 for my oncology fellowship and to work in Jay Levy’s retrovirus lab. But when an ID giant, Merle Sande, offered me the chance to start a medical oncology division at San Francisco General Hospital immediately following the end of my training, I eagerly accepted. I left retrovirus research forever, only to walk into the very beginning of the AIDS epidemic on July 1,st 1981, when I saw the first Kaposi sarcoma KSpatient admitted to SFGH. I started the world’s first comprehensive AIDS clinic with Connie Wofsy, my ID counterpart in 1983 and when HIV was discovered (in part by Jay), I realized I might get back to my favorite viruses! While I still feel as if part of me is in oncology, my community is clearly ID! Definitely hooked on ID!